



**Press Release**

**Distribution date: 24 January 2018**

## **Hikma Pharmaceuticals Participates in World Economic Forum in Switzerland**

*Marking a decade of its involvement*

Amman, January 2018 – For its tenth consecutive year, **Hikma Pharmaceuticals** – the fast growing multinational pharmaceutical group – joins change-makers in its industry at the World Economic Forum (WEF) Annual Meeting in Davos, Switzerland. Featuring His Majesty King Abdullah II ibn Al Hussein and many distinguished speakers, the 48th Forum is taking place from 23 – 26 January, 2018, under the theme ‘Creating a Shared Future in a Fractured World’.

Through its partnership with the WEF as a Health Industry Associate, **Hikma** joins a network of health industry leaders, including global pharmaceutical companies, major health centers and hospitals, and top research and development centers and universities, to advance the state of global health.

Representing the Company at the Forum, **Hikma** Executive Vice Chairman, President and CEO of MENA and Emerging Markets, Mazen Darwazah, is a contributing speaker at an official session titled, ‘Going Digital in the Arab World.’ Also participating in the session are H.E. Sheikha Bodour bint Sultan bin Muhammad Al Qasimi, the Chairperson of the Sharjah Investment and Development Authority, Antonio Neri of Hewlett Packard Enterprise and Mohammed Alshaya of Alshaya Group, among others.

Darwazah also joins forces with the World Bank and the Red Cross (ICRC) in another session, ‘Rethinking Humanitarian Finance’, which tackles the vital issue of growing humanitarian needs, including forced displacement and how business, humanitarian and development parties can work together to deploy innovative financing solutions.

“Through its global operations, **Hikma** impacts communities around the world, working tirelessly to advance health in its locations in the MENA region, Europe and the US, as well as providing humanitarian assistance to those in need, including refugees,” said Darwazah. “Additionally, the field of e-health is one we have a keen interest in, as it presents numerous solutions to overcoming existing barriers. For this reason, Hikma Ventures – the corporate venture capital arm of **Hikma** Pharmaceuticals – is moving towards fostering a startup ecosystem by embracing a digital mindset and investing in upcoming digital health startups. This reaffirms **Hikma**’s mission

of providing patients with better access to high-quality, affordable medicines in key therapeutic areas.”

**-Ends-**

**About Hikma Pharmaceuticals**

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: “Branded”, “Injectables” and “Generics”, based primarily in the Middle East and North Africa (“MENA”) region, where it is a market leader, the United States and Europe. Hikma currently employs over 8,500 staff members worldwide.

***This press release has been distributed by Bidaya Corporate Communications on behalf of Hikma Pharmaceuticals.***

***For more information or assistance, please contact us at:***



**BIDAYA**  
CORPORATE COMMUNICATIONS

**Tel:** +962 6 585 4002/6

**Fax:** +962 6 585 3001

**P.O. Box:** 930391, Amman 11193, Jordan

**Email:** [media@bidayacorp.com](mailto:media@bidayacorp.com)